Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer - Hata, Taishi; Uemura, Mamoru; Danno, Katsuki; Yoshioka, Shinichi; Matsuda, Chu; Kagawa, Yoshinori; Shingai, Tatsushi; Suzuki, Yozo; Tei, Mitsuyoshi; Tanida, Tsukasa; Komori, Takamichi; Okamura, Shu; et al. (Scientific reports, 2024)
Keywords: 631/67; 631/67/1059; 631/67/1059/99; Adjuvant chemotherapy; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer therapies; Capecitabine - administration & dosage; Capecitabine - adverse effects; Capecitabine - therapeutic use; Chemotherapy, Adjuvant - adverse effects; Colon cancer; Colonic Neoplasms - drug therapy; Colonic Neoplasms - pathology; Colorectal cancer; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Disease management; Disease-Free Survival; East Asian People; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Fluorouracil - analogs & derivatives; Fluorouracil - therapeutic use; Humanities and Social Sciences; Humans; Japan; Japanese; Male; Medical prognosis; Middle Aged; multidisciplinary; Neoplasm Staging; Neuropathy; Oxaliplatin; Oxaliplatin - administration & dosage; Oxaliplatin - adverse effects; Oxaliplatin - therapeutic use; Oxaloacetates; Patients; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - etiology; Peripheral neuropathy; Peripheral sensory neuropathy; Prospective Studies; Science; Science (multidisciplinary); Survival; Treatment Outcome; XELOX; Japan; XELOX; Adjuvant chemotherapy; Peripheral sensory neuropathy; Japanese